RxDoctor Payments Data

Kamala Fields, NP

Family · Greenville, TXNPI 1558471995

Payments from drug & device makers

$8,133in general payments, 2019–2025

Across 464 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$677
  • Alkermes, Inc.$529
  • Otsuka America Pharmaceutical, Inc.$520
  • Vanda Pharmaceuticals Inc.$471
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,133 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$26,175
Medicare patients
44
Services billed
377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$63,313
VraylarCariprazine Hcl36$57,695
Atomoxetine Hcl43$3,168
Lurasidone Hcl46$2,207
Quetiapine Fumarate133$1,981
Aripiprazole101$1,722
Bupropion XlBupropion Hcl93$1,688
Vilazodone Hcl17$1,657
Buspirone Hcl91$1,530
Duloxetine Hcl74$1,472
Clonazepam157$1,373
Trazodone Hcl181$1,147
Ziprasidone Hcl33$1,063
Alprazolam208$1,027
Divalproex Sodium ErDivalproex Sodium40$950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$231$63,31319 claims
AbbVieVraylar$1,310$57,69536 claims
Almatica Pharma LLCSertraline Hcl$114$678107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Greenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →